Idorsia Ltd is a Swiss biopharmaceutical company founded in 2017 as a spin-off from Actelion following its acquisition by Johnson & Johnson. Headquartered in Allschwil, Switzerland, Idorsia focuses on the discovery, development and commercialization of innovative small-molecule therapeutics. The company’s R&D efforts span multiple therapeutic areas, including neuroscience, cardiovascular and immunology, with the goal of addressing unmet medical needs through novel mechanisms of action.
Among Idorsia’s lead products is daridorexant, a dual orexin receptor antagonist developed for the treatment of insomnia. This medicine has received regulatory approval in key markets and represents the company’s first commercial offering. In addition to daridorexant, Idorsia’s pipeline features several clinical-stage candidates, including an endothelin receptor antagonist for resistant hypertension and compounds targeting rare diseases, pulmonary arterial hypertension and various immune-mediated conditions.
Idorsia serves patients and healthcare providers across Europe, North America and Asia, operating through strategically located offices and research sites. The company maintains partnerships with academic institutions and industry collaborators to accelerate the translation of early-stage discoveries into late-stage development programs. Its global footprint supports both clinical development and potential future commercialization efforts in multiple territories.
Leadership at Idorsia is headed by co-founders Jean-Paul and Martine Clozel, who bring extensive experience in drug discovery and pharmaceutical development. Together with a multidisciplinary management team, they oversee a workforce of scientists, clinicians and business professionals dedicated to advancing Idorsia’s mission of bringing transformative therapies to patients worldwide.
AI Generated. May Contain Errors.
